Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

被引：1
|
作者：
Trarbach, T. [1 ]
Drevs, J. [2 ]
Strumberg, D. [3 ]
Gauler, T. C. [1 ]
Schneider, V. [2 ]
Eberhardt, W. E. [1 ]
Collins, B. [4 ]
Marotti, M. [4 ]
Swaisland, A. J. [4 ]
机构：
[1] Univ Essen Gesamthsch, Sch Med, W German Canc Ctr, Essen, Germany
[2] Canc Hosp SanaFontis, Freiburg, Germany
[3] Marienhosp Herne, Herne, Germany
[4] AstraZeneca, Macclesfield, Cheshire, England
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)70442-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [1] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Tanja Trarbach
    Beate Schultheis
    Thomas C. Gauler
    Vesile Schneider
    Dirk Strumberg
    Wilfried E. E. Eberhardt
    Stephanie Le Scouiller
    Marcelo Marotti
    Kathryn H. Brown
    Joachim Drevs
    Investigational New Drugs, 2012, 30 : 1962 - 1971
  • [2] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
    Trarbach, Tanja
    Schultheis, Beate
    Gauler, Thomas C.
    Schneider, Vesile
    Strumberg, Dirk
    Eberhardt, Wilfried E. E.
    Le Scouiller, Stephanie
    Marotti, Marcelo
    Brown, Kathryn H.
    Drevs, Joachim
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1962 - 1971
  • [3] A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Marotti, M.
    Puchalski, T. A.
    Swaisland, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
    Renouf, Daniel J.
    Moore, Malcolm J.
    Hedley, David
    Gill, Sharlene
    Jonker, Derek
    Chen, Eric
    Walde, David
    Goel, Rakesh
    Southwood, Bernadette
    Gauthier, Isabelle
    Walsh, Wendy
    McIntosh, Lynn
    Seymour, Lesley
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 779 - 786
  • [5] A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
    Daniel J. Renouf
    Malcolm J. Moore
    David Hedley
    Sharlene Gill
    Derek Jonker
    Eric Chen
    David Walde
    Rakesh Goel
    Bernadette Southwood
    Isabelle Gauthier
    Wendy Walsh
    Lynn McIntosh
    Lesley Seymour
    Investigational New Drugs, 2012, 30 : 779 - 786
  • [6] Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    Kaye, S.
    Aamdal, S.
    Jones, R.
    Freyer, G.
    Pujade-Lauraine, E.
    de Vries, E. G. E.
    Barriuso, J.
    Sandhu, S.
    Tan, D. S-W
    Hartog, V.
    Kuenen, B.
    Ruijter, R.
    Kristensen, G. B.
    Nyakas, M.
    Barrett, S.
    Burke, W.
    Pietersma, D.
    Stuart, M.
    Emeribe, U.
    Boven, E.
    BRITISH JOURNAL OF CANCER, 2012, 106 (11) : 1728 - 1734
  • [7] Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
    S Kaye
    S Aamdal
    R Jones
    G Freyer
    E Pujade-Lauraine
    E G E de Vries
    J Barriuso
    S Sandhu
    D S-W Tan
    V Hartog
    B Kuenen
    R Ruijter
    G B Kristensen
    M Nyakas
    S Barrett
    W Burke
    D Pietersma
    M Stuart
    U Emeribe
    E Boven
    British Journal of Cancer, 2012, 106 : 1728 - 1734
  • [8] First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours
    Fujisaka, Yasuhito
    Onozawa, Yusuke
    Kurata, Takayasu
    Yasui, Hirofumi
    Goto, Isao
    Yamazaki, Kentaro
    Machida, Nozomu
    Watanabe, Junichiro
    Shimada, Hitoshi
    Shi, Xiaojin
    Boku, Narikazu
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 108 - 114
  • [9] Effects on bone turnover of the potent, once-daily, oral Src inhibitor AZD0530 in patients with advanced solid malignancies
    Hannon, R. A.
    Finkelman, R. D.
    Clack, G.
    Iacona, R. B.
    Baker, P.
    Rimmer, M.
    Gossiel, F.
    Smith, I. C.
    Robinson, A.
    Eastell, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S410 - S410
  • [10] AZD0530, a potent, once-daily, oral Src inhibitor reduces bone resorption in patients with advanced solid malignancies
    Hannon, R. A.
    Finkelman, R. D.
    Clack, G.
    Iacona, R. B.
    Baker, P.
    Rimmer, M.
    Gossiel, F.
    Smith, I. C.
    Robinson, A.
    Eastell, R.
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 53 - 54
12345